Sign up now and fund within 24h to get free NKE, GPRO or DBX stock. T&Cs apply.
Redeem Now
PURETECH HEALTH PLC - ADR

Kickstart your portfolio with a U.S. stock on us

Sign up and fund a new Wall St account and get a full U.S. share.T&Cs apply

Claim now
Kickstart your portfolio with a U.S. stock on us

About PRTC

PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.

Find out what a historical investment in PURETECH HEALTH PLC - ADR would be worth today using our PRTC stock calculator.

Market Capitalisation

$424.42M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

7.18K

High today

$17.84

Low today

$17.25

Open price

$17.44

52-week high

$19.92

52-week low

$14.50

Ready to start your investing journey with Stake?

Open an account
Buying PRTC shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in PURETECH HEALTH PLC - ADR in minutes.
  1. Sign up with some I.D. and zero paperwork
  2. Add funds to your account
  3. Make your first investment in PRTC

The ticker symbol for PURETECH HEALTH PLC - ADR is PRTC.

One share of PRTC is valued at $17.74 as of 20 May 2026.

As of 20 May 2026 PURETECH HEALTH PLC - ADR has a market cap of $424.42M.

The PURETECH HEALTH PLC - ADR 52-week high stock price is $19.92.

The PURETECH HEALTH PLC - ADR 52-week low stock price is $14.50.

Yes, the Stake investing platform allows you to buy PRTC shares and over 12,000 more stocks and ETFs across the ASX and Wall St.

This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Stake app

Invest in PRTC on Stake

  • Buy PRTC from US$3 brokerage
  • Invest in 9,500+ U.S. stocks and ETFs
  • Own a slice of PRTC from only US$10 with fractional shares
Get started

Stock shown for demonstrative purposes only. US$3 brokerage up to US$30,000.

PRTC related stocks

Footer


Made in Australia

Sydney, Australia

Subscribe to our newsletter

By subscribing, you agree to our Privacy Policy.



Get the app

Scan QR code to download the app

Stakeshop Pty Ltd, trading as Stake, ACN 610 105 505, is an authorised representative (Authorised Representative No. 1241398) of Stakeshop AFSL Pty Ltd (Australian Financial Services Licence no. 548196). Stake SMSF Pty Ltd ACN 648 283 532 (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. For more information about SMSFs, see our SMSF Risks page. The Stake Accumulate Fund (ARSN 680 653 374) is issued by K2 Asset Management Ltd (ABN 95 085 445 094 AFSL 244 393), a wholly owned subsidiary of K2 Asset Management Holdings Ltd (ABN 59 124 636 782). The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services GuideTerms & ConditionsPrivacy Policy and Disclaimers before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

Copyright © 2026 Stake. All rights reserved.